April 2
Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
Read moreBrandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areVaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solution
View ProjectDeveloping a new class of therapeutics that enhance the function of beneficial proteins
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectWe conduct eye research with real-life impact. We are unravelling the causes of diseases, preventing blindness through earlier diagnosis and better treatments, and restoring sight.
ViewOur vision is to perform world-class medical research that focuses on the molecular basis of health and disease. The specific areas of our research include cancer, molecular bioscience, metabolic and musculoskeletal medicine, infection and immunity.
ViewPeter Mac is one of the world’s leading cancer research, education and treatment centres globally and is Australia’s only public hospital solely dedicated to caring for people affected by cancer. There are over 2,500 staff, including more than 600 laboratory and clinical researchers, all focused on providing better treatments, better care and potential cures for cancer.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreAzura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
Read more$3 million in Funding to Support Early-Stage Biomedtech Projects Focused on Minimising Antimicrobial Resistance Thanks to the CSIRO
Read moreBrandon BioCatalyst, in partnership with ANDHealth, selected by Federal Government to deliver $50m Dementia and Cognitive Decline Incubator
Read moreAravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
Read more